The three SSc skin biopsies with elevated extracellular TGM2 showed reduced TG activity in the dermis after zampilimab treatment, indicating TGM2‐specific activity (Supplemental Figure 1E and F). This evidence concerns the gene TGM2 and systemic sclerosis.